Earnings Alerts

Chemed Corp (CHE) Earnings: 2025 Adjusted EPS Forecast Surpasses Estimates

By February 27, 2025 No Comments
  • Chemed’s adjusted earnings per share (EPS) forecast for 2025 exceeded market estimates, ranging between $24.95 to $25.45, while market estimates were at $24.89.
  • For the fourth quarter, the company’s adjusted EPS was reported at $6.83, up from $6.60 year-over-year, surpassing the estimated $6.78.
  • The service revenue for the fourth quarter was $640.0 million, reflecting a 9.2% increase year-over-year, and exceeded the estimated $636.3 million.
  • The stock has a strong market sentiment with 3 ‘buy’ ratings and no ‘hold’ or ‘sell’ recommendations.

Chemed Corp on Smartkarma

Smartkarma analysts, including Baptista Research, are closely monitoring Chemed Corp and providing valuable insights to investors. According to Baptista Research‘s reports on Chemed Corp, the company’s third-quarter 2024 earnings showcased a mixed performance between its two main segments, VITAS Healthcare and Roto-Rooter. While VITAS Healthcare exhibited strong growth fueled by increased admissions and the successful Covenant Health acquisition, Roto-Rooter faced challenges that the management is striving to address.

Furthermore, Baptista Research‘s analysis delves into the integration of Covenant Health by Chemed Corp, highlighting the company’s diversified nature operating through VITAS Healthcare Corporation and Roto-Rooter. The Second Quarter 2024 Earnings Call updates emphasized a nuanced performance across the operations, with VITAS Healthcare Corporation showing a notable positive momentum, especially following the acquisition of Covenant Health. This insightful coverage provides investors with a comprehensive view of Chemed Corp‘s key drivers and risks, aiding in informed investment decisions.


A look at Chemed Corp Smart Scores

FactorScoreMagnitude
Value2
Dividend2
Growth3
Resilience4
Momentum3
OVERALL SMART SCORE2.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Chemed Corp, a healthcare company primarily operating through its subsidiary Vitas Healthcare Corporation, is expected to have a promising long-term outlook according to Smartkarma Smart Scores. With a score of 3 for Growth and 4 for Resilience, the company appears to have significant potential for expansion and a strong ability to withstand challenges in the market. Additionally, receiving a score of 3 for Momentum suggests that Chemed Corp is showing positive movement in the right direction. While the Value and Dividend scores are at 2, indicating average performance in these areas, the overall outlook for Chemed Corp seems optimistic.

Chemed Corp‘s presence in the healthcare field, alongside its involvement in the repair-and-maintenance-service industry through brands like Roto-Rooter and Service America Network Inc, provides a diversified business model. This diversification, coupled with the growth potential highlighted by the Smart Scores, positions Chemed Corp well for future success. Investors may find the company attractive based on its solid Resilience score and the positive Momentum it is currently experiencing, indicating a company on the rise within its respective industries.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars